Toll-like Receptor 3 c.1377C/T and -7C/A Polymorphisms Associated with COVID-19 and COVID-19 Severity
Abstract
Chinese officials have reported the novel coronavirus to the world health organization, which is called the SARS-CoV-2. Toll-like receptor 3 (TLR3) induces antiviral immune responses via the production of type I interferons and inflammatory cytokines. In this study, we aimed to examine TLR3 c.1377C/T and -7C/A polymorphisms in COVID-19 and the association between some clinical parameters. We investigated the frequencies of TLR3 (c.1377C/T and -7C/A) polymorphisms in 150 patients with COVID-19 and 171 healthy individuals as controls. We performed polymerase chain reaction (PCR) based on restriction fragment length polymorphism (RFLP). We also investigated whether TLR3 c.1377C/T and-7C/A were associated with the severity of COVID-19. In addition, CHAID tree-based classification algorithm was created to investigate the severity of the patients in our study. TLR3 c.1377C/T TT genotype frequencies were statistically significant between cases and controls (p= 0.02). For TLR3 -7C/A polymorphism, the findings showed a statistically significant difference in A allele frequencies (p= 0.03). There was a statistically significant difference in the distribution of TLR3 -7C/A CA genotype frequency (p= 0.04). Our findings suggest that TLR3 c.1377C/T and -7C/A polymorphisms may be important on susceptibility or clinical course of COVID-19.
Keywords
COVID-19, Genetic polymorphism, Severity, Toll like receptor 3, CHAID tree-based classification algorithm.
Project Number
F-2021-635
References
- [1] Shang J., Wan Y., Liu C., Yount B., Gully K., Yang Y., Structure of mouse coronavirus spike protein complexed with receptor reveals mechanism for viral entry, PLoS Pathog, 3 (2020) 9-16.
- [2] Chen Y., Liu Q., & Guo D., Emerging coronaviruses: genome structure, replication, and pathogenesis, Journal of Medical Virology, 92 (2020) 418-423.
- [3] Gorbalenya A.E., Baker S.C., Baric R.S., Groot R.J., Drosten C., Gulyaeva A.A., The species severe acute respiratory syndrome related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2, Nat Microbiol., 5 (2020) 536–544.
- [4] WHO 2022 (2022, February 23). Retrieved from https://www.who.int/emergencies/diseases/novel-coronavirus-2019
- [5] Hoechter D.J., Becker-Pennrich A., Langrehr J., Bruegel M., Zwissler B., Schaefer S., Higher procoagulatory potential but lower DIC score in COVID-19 ARDS patients compared to non-COVID-19 ARDS patients, Thromb Res., 196 (2020) 186-192.
- [6] Park S.E., Epidemiology, virology, and clinical features of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2; Coronavirus Disease-19), Clinical and Experimental Pediatric, 63(4) (2020) 119.
- [7] Wu F., Zhao S., Yu B., Chen Y.M., Complete genome characterisation of a novel coronavirus associated with severe human respiratory disease in Wuhan, China, BioRxiv, (2020).
- [8] Cui J., Li F., Shi Z.L., Origin and evolution of pathogenic coronaviruses, Nature Reviews Microbiology, 17(3) (2019) 181-192.
- [9] Zhou P., Yang X.L., Wang X.G., Hu B., Zhang L., Zhang W., A pneumonia outbreak associated with a new coronavirus of probable bat origin, Nature, 579(7798) (2020) 270-273.
- [10] Wan Y., Shang J., Graham R., Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus, Journal of Virology. 94(7) (2020) e00127-20.